홈 > 시장보고서 > 의약품

시장보고서

상품코드

1767679

허셉틴(Herceptin) 시장 : 유형별, 용도별, 유통 채널별, 지불자 유형별, 투여 경로별, 치료 라인별, 환자 속성별, 지역별

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

발행일: 2025년 06월 | 리서치사:

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

허셉틴 시장은 2025년에 33억 달러, 2032년에는 48억 4,000만 달러에 이를 것으로 예측되며, 2025-2032년 연평균 복합 성장률(CAGR)은 5.62%를 나타낼 전망입니다.

분석 범위		분석 상세
기준 연도	2024년	시장 규모(2025년)	33억 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 CAGR(2025-2032년)	5.62%	예측 금액(2032년)	48억 4,000만 달러

세계 허셉틴 시장은 HER2 양성 유방암의 유병률 증가와 표적치료제에 대한 수요 증가에 힘입어 최근 몇 년 동안 괄목할 만한 성장을 거듭하고 있습니다. 트라스투주맙으로도 알려진 허셉틴은 유방암의 약 20-30%에서 과발현되는 HER2 단백질을 특이적으로 표적하는 단일클론항체입니다.

이 약은 HER2 양성 유방암의 치료 환경에 혁명을 일으켜 환자의 예후와 생존율을 향상시켰습니다. HER2 양성 전이성 위암 치료 등 허셉틴의 적응증 확대로 시장 성장은 더욱 가속화되고 있습니다. 또한, 허셉틴의 바이오시밀러 개발 및 다른 치료법과의 병용을 통한 허셉틴의 채택 확대는 시장 성장의 새로운 길을 열어주고 있습니다. 본 보고서에서는 세계 허셉틴 시장을 상세하게 분석하여 시장 성장 촉진요인, 시장 성장 저해요인, 기회, 미래 전망 등을 파악하고자 합니다.

시장 역학:

세계 허셉틴 시장은 HER2 양성 유방암 발병률 증가, 표적치료에 대한 인식 증가, 맞춤의료에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 또한 HER2 발현에 대한 동반 진단 검사의 개발로 허셉틴 치료가 가장 효과적일 것으로 예상되는 환자를 식별할 수 있게 되어 시장 성장에 기여하고 있습니다. 그러나 허셉틴 치료는 고가이기 때문에 일부 지역에서는 사용이 제한될 수 있어 시장 성장을 제한하고 있습니다. 또한, 바이오시밀러의 출현과 일부 국가에서 허셉틴의 특허가 만료되는 것도 오리지널 의약품 시장 점유율에 영향을 미칠 수 있습니다. 이러한 도전에도 불구하고 허셉틴의 다른 HER2 양성 암에 대한 적응증 확대, 새로운 약물의 병용요법 개발, 신흥국에서의 허셉틴 채택 확대 등 시장 성장 기회는 여전히 존재합니다. 또한, 허셉틴의 유효성 및 안전성 향상을 위한 연구개발이 진행되고 있어 향후 시장 성장의 원동력이 될 것으로 기대됩니다.

본 보고서의 주요 특징

세계의 허셉틴(Herceptin) 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
세계 허셉틴 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 작성되었습니다.
이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
'세계 허셉틴 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 허셉틴 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 3.30 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.62%	2032 Value Projection:	USD 4.84 Bn

The global Herceptin market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.

The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the global Herceptin market, highlighting its key drivers, restraints, opportunities, and future prospects.

Market Dynamics:

The global Herceptin market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global Herceptin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Herceptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Herceptin market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Biologic
- Biosimilars
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer Treatment
- Gastric Cancer Treatment
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Payer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
Administration Route Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
Treatment Line Insights (Revenue, USD Bn, 2020 - 2032)
- First-line Treatment
- Second-line Treatment
- Third-line Treatment
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Pediatric
- Adult
- Geriatric
- Gender
- Male
- Female
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Genentech (Roche)
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK (GlaxoSmithKline)
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Herceptin Market, By Type
- Global Herceptin Market, By Application
- Global Herceptin Market, By Distribution Channel
- Global Herceptin Market, By Payer Type
- Global Herceptin Market, By Administration Route
- Global Herceptin Market, By Treatment Line
- Global Herceptin Market, By Patient Demographics
- Global Herceptin Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Breast Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gastric Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
First-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Second-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Third-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Pediatric
  - Adult
  - Geriatric
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Male
  - Female

11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

Genentech (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
EMD Serono
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

13. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

14. References and Research Methodology

References
Research Methodology
About us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,676,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,385,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,837,000

※ 부가세 별도

허셉틴(Herceptin) 시장 : 유형별, 용도별, 유통 채널별, 지불자 유형별, 투여 경로별, 치료 라인별, 환자 속성별, 지역별

Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography

시장 역학:

본 보고서의 주요 특징

목차

제1장 분석 목적과 전제조건

제2장 시장 전망

제3장 시장 역학, 규제 및 동향 분석

제4장 세계의 허셉틴 시장 : 유형별(2020-2032년)

제5장 세계의 허셉틴 시장 : 용도별(2020-2032년)

제6장 세계의 허셉틴 시장 : 유통 채널별(2020-2032년)

제7장 세계의 허셉틴 시장 : 지불자 유형별(2020-2032년)

제8장 세계의 허셉틴 시장 : 투여 경로별(2020-2032년)

제9장 세계의 허셉틴 시장 : 치료 라인별(2020-2032년)

제10장 세계의 허셉틴 시장 : 환자 속성별(2020-2032년)

제11장 세계의 허셉틴 시장 : 지역별(2020-2032년)

제12장 경쟁 구도

제13장 애널리스트의 제안

제14장 참고 문헌과 조사 방법